InsidersTradesSigma
Total declarations
Company
▲ Purchases (13 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Robbins Wendye, Director. Director active across 1 companies, notably RAPT Therapeutics, Inc.. Aggregated, 13 filings have been recorded. Total volume traded: €156k. The latest transaction was filed on 10 May 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations13 total
€20,0132,000 shares@ €10.006712.9% of flow
Common Stock
SEC:0001593968-22-000958:0·
Ideal exit: 4 Feb 2023 (T+270)
€13,217500 shares@ €26.433919.5% of flow
Common Stock
SEC:0001593968-21-002279·
Ideal exit: 15 Jul 2022 (T+270)
€13,217500 shares@ €26.43398.5% of flow
Common Stock
SEC:0001593968-21-002279:0·
Ideal exit: 15 Jul 2022 (T+270)
€10,238400 shares@ €25.595715.1% of flow
Common Stock
SEC:0001593968-21-002276·
Ideal exit: 10 Jul 2022 (T+270)
€10,238400 shares@ €25.59576.6% of flow
Common Stock
SEC:0001593968-21-002276:0·
Ideal exit: 10 Jul 2022 (T+270)
€13,246500 shares@ €26.492719.5% of flow
Common Stock
SEC:0001593968-21-002027·
Ideal exit: 20 May 2022 (T+270)
€13,246500 shares@ €26.49278.5% of flow
Common Stock
SEC:0001593968-21-002027:0·
Ideal exit: 20 May 2022 (T+270)
€2,553100 shares@ €25.5343.8% of flow
Common Stock
SEC:0001593968-21-002007·
Ideal exit: 17 May 2022 (T+270)
€2,553100 shares@ €25.5341.6% of flow
Common Stock
SEC:0001593968-21-002007:0·
Ideal exit: 17 May 2022 (T+270)
€15,365600 shares@ €25.607522.7% of flow
Common Stock
SEC:0001593968-21-001818·
Ideal exit: 3 Apr 2022 (T+270)
€15,365600 shares@ €25.60759.9% of flow
Common Stock
SEC:0001593968-21-001818:0·
Ideal exit: 3 Apr 2022 (T+270)
€13,147500 shares@ €26.29319.4% of flow
Common Stock
SEC:0001593968-21-001661·
Ideal exit: 13 Mar 2022 (T+270)
€13,147500 shares@ €26.2938.5% of flow
Common Stock
SEC:0001593968-21-001661:0·
Ideal exit: 13 Mar 2022 (T+270)
13 of 13 declarations
About Robbins Wendye
Wendye Robbins serves as a Director at RAPT Therapeutics, Inc. She contributes to the company's governance and strategic decision-making. Her experience in the pharmaceutical sector is valuable to the board.
